Labgenomics Co

Labgenomics Co Earnings Yield

The Earnings Yield of Labgenomics Co (084650.KQ) as of Nov 5, 2026 is -51.46 %. In the previous year, Earnings Yield was -19.02 % — a change of 170.53% (lower).

Earnings Yield

-51.46 %

YoY

170.53%

Last updated:

Earnings Yield of Labgenomics Co is 2025 -51.46 % . Earnings Yield of Labgenomics Co was 2024 -19.02 % . It decreases by 170.53% lower compared to the previous year.

The Labgenomics Co Earnings Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Earnings Yield
Date
Earnings Yield
Jan 1, 2018
-3.18 KRW
Jan 1, 2019
0.77 KRW
Jan 1, 2020
34.19 KRW
Jan 1, 2021
67.03 KRW
Jan 1, 2022
38.69 KRW
Jan 1, 2023
-3.74 KRW
Jan 1, 2024
-19.02 KRW
Jan 1, 2025
-51.46 KRW
The Labgenomics Co Earnings Yield history
YEAREarnings YieldYoY
-51.46 %+170.53%
-19.02 %+409.12%
-3.74 %-109.66%
38.69 %-42.28%
67.03 %+96.08%
34.19 %+4,343.63%
0.77 %-124.23%
-3.18 %+15.61%
-2.75 %-574.97%
0.58 %-55.51%
1.30 %-32.80%
1.93 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Labgenomics Co Stock analysis

What does Labgenomics Co do? LabGenomics Co., Ltd. generates revenue through the provision of in vitro diagnostic (IVD) products and services. The company offers general diagnostic check services, molecular diagnostic check services, and research and development services, alongside IVD products such as DNA chips and PCR kits. Its diagnostic services include examinations for breast cancer and colorectal cancer, while its biosensor solutions target point of care testing (POCT). Additionally, LabGenomics sells healthy food as part of its product portfolio. The primary buyers of LabGenomics' services are healthcare institutions requiring diagnostic support, including hospitals and clinics. The company's molecular diagnostic services and cancer examinations are particularly sought after by medical facilities focused on specialized testing. Healthcare providers also purchase its biosensor solutions for immediate testing at the point of care. LabGenomics' product segments include IVD services, IVD products like DNA chips and PCR kits, cancer examination services, and healthy food. The company's molecular diagnostic services and cancer testing are key revenue drivers, while its biosensor for POCT and healthy food offerings serve complementary market segments. Labgenomics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Labgenomics Co stock

Earnings Yield of Labgenomics Co is -51.46 % in 2025.

Earnings Yield of Labgenomics Co changed from -19.02 % to -51.46 %, representing a 170.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Earnings Yield Labgenomics Co since 2006 – with annual values, charts, and detailed analysis.

Earnings Yield is the inverse of the P/E ratio. It shows the percentage of each dollar invested that was earned by the company. Higher earnings yield indicates better value.

To evaluate Earnings Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Earnings Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Earnings Yield's Labgenomics Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Labgenomics Co

All Key Metrics — Labgenomics Co